McKesson Corporation (MCK) Stock Analysis
Recovery setup
Healthcare · Medical Distribution
Sell if holding. Engine safety override at $785.43: Quality below floor (3.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.4/10. Specifically: Below-average business quality; Below long-term trend.
McKesson is a diversified healthcare services company with four segments—North American Pharmaceutical distribution, Oncology & Multispecialty, Prescription Technology Solutions, and Medical-Surgical Solutions—serving pharmacies, hospitals, and providers across North America.... Read more
Sell if holding. Engine safety override at $785.43: Quality below floor (3.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.4/10. Specifically: Below-average business quality; Below long-term trend. Chart setup: Death cross but MACD improving, RSI 63. Score 5.4/10, moderate confidence.
Passes 4/7 gates (clean insider activity, earnings proximity 50d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and favorable risk/reward ratio. Suitability: moderate.
About McKesson Corporation
About McKesson Corporation
McKesson Corporation distributes branded, generic, specialty, biosimilar, and OTC pharmaceuticals through 27 U.S. distribution centers and approximately 2,600 Canadian independent pharmacy franchises, competing directly with Cencora, Inc. and Cardinal Health, Inc. across North American pharmaceutical distribution. Four operating segments employed more than 43,000 people as of March 31, 2026 — roughly 38,000 in the U.S., 5,000 in Canada, and 400 internationally — making McKesson one of the largest pharmaceutical distributors in North America.
McKesson earns revenue through pharmaceutical wholesale to three primary U.S. channels: retail national accounts (chain pharmacies, mail-order, mass merchandisers), community pharmacies (including the Health Mart franchise network of approximately 3,900 locations), and institutional providers such as hospitals and integrated delivery networks. The Oncology & Multispecialty segment supports the U.S. Oncology Network, holds an 80% controlling interest in PRISM Vision for ophthalmology, and a 51% stake in Sarah Cannon Research Institute. The Prescription Technology Solutions segment connects more than 50,000 pharmacies and 1,000,000 providers to 650+ biopharma brands, helping patients access medicines more than 135 million times annually and save about $10 billion on medications. Generic sourcing is conducted through ClarusONE Sourcing Services LLP, a joint venture with Walmart Inc.
Show full overview
McKesson's most pronounced litigation exposure is its role as a defendant in opioid distribution cases brought by governmental entities — states, counties, and municipalities — and the company is subject to consent decrees issued by state courts governing controlled substance distribution. In April 2026, the company disclosed via Form 8-K the refinancing of credit facilities, entering a new revolving credit agreement with Bank of America as administrative agent while terminating the existing $1.0 billion 364-day and $4.0 billion five-year senior unsecured revolving credit facilities. The planned separation of Medical-Surgical Solutions into an independent publicly traded company — contingent on a favorable tax-free ruling, SEC registration effectiveness, Board approval, and regulatory clearances — adds execution complexity over the near term.
See also: Healthcare · Medical Distribution
From McKesson Corporation's most recent 10-K filing, extracted June 11, 2026.
Recent developments
updated 2026-06-17Recent Developments — McKesson Corporation
Latest news
- NEWS If You Invested $100 In McKesson Stock 5 Years Ago, You Would Have This Much Today — benzinga Jun 16, 2026
- NEWS Barclays Maintains Overweight on McKesson, Lowers Price Target to $925 — benzinga Jun 10, 2026 neutral
- NEWS Here's How Much $100 Invested In McKesson 20 Years Ago Would Be Worth Today — benzinga Jun 8, 2026 positive
- NEWS Amazon Ends Walmart's 13‑Year Hold On The S&P 500 Revenue Crown — But There's A Catch — benzinga Jun 3, 2026 positive
- NEWS McKesson Announces Completion Of Previously-Announced $1.25B Minority Ownership Investment By Apollo Funds For 13% Of MC — benzinga Jun 2, 2026 positive
Generated 2026-06-17T09:12:25Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Material Events(8-K, last 90d)
- 2026-04-28Item 1.02MEDIUMMcKesson terminated its existing $1.0B 364-day and $4.0B five-year revolving credit facilities on April 24, 2026, replacing them with a new consolidated $5B revolving credit facility. Successor agreement in place.SEC filing →
- 2026-03-05Item 5.02MEDIUMCFO Britt J. Vitalone gave notice of retirement; last day as CFO May 28, 2026. Kenny K. Cheung (former CFO of Sysco) appointed new CFO effective May 29, 2026. Clean handoff.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $785.43: Quality below floor (3.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.4/10. Specifically: Below-average business quality; Below long-term trend. Chart setup: Death cross but MACD improving, RSI 63. Prior stop was $750.55. Score 5.4/10, moderate confidence.
Take-profit target: $847.26 (+7.9% upside). Prior stop was $750.55. Stop-loss: $750.55.
Quality below floor (3.5 < 4.0).
McKesson Corporation trades at a P/E of 20.3 (forward 15.5). TrendMatrix value score: 6.4/10. Verdict: Sell.
23 analysts cover MCK with a consensus score of 4.3/5. Average price target: $941.
What does McKesson Corporation do?McKesson is a diversified healthcare services company with four segments—North American Pharmaceutical distribution,...
McKesson is a diversified healthcare services company with four segments—North American Pharmaceutical distribution, Oncology & Multispecialty, Prescription Technology Solutions, and Medical-Surgical Solutions—serving pharmacies, hospitals, and providers across North America. With 43,000+ employees and 27 U.S. pharmaceutical distribution centers, it has announced plans to separate its Medical-Surgical segment.